Genentech is planning a massive overhaul of its 207-acre South San Francisco campus that could cost between $3B and $5B by the time the multiphase project is complete, according to the San Francisco ...

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global ...

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical-stage biopharmaceutical ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape ...

The story behind the development of immune checkpoint inhibitors, fulfilling the promise of cancer immunotherapy ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered subcutaneo ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [ NCT05171647 ] study showing Lunsumio ® (mosunetuzumab-axgb) administered ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...